Trials

Ongoing trials:

First line of treatment

KRd consolidation in myeloma patients with a positive PET-CT after standard first line treatment. A phase II study
HOVON129 - Treatment of primary plasma cell leukemia
Hovon147 - Carfilzomib, Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone in High- Risk Smoldering Multiple Myeloma: A Randomized Phase II Study.
Ithaca: Isatuximab-Rd vs Rd for patients with high risk smouldering myeloma
REMNANT: Two-line study for patients eligible for transplant
ISKIA: Isatuximab-carfilzomib-dexamethason with ASCT for newly diagnosed patients

Relapse or refractory

Combined carfilzomib and hydroxychloroquine in patients with relapsed / refractory multiple myeloma – A phase I trial
An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients with AL Amyloidosis Following at Least One Prior Line of Therapy
A Phase I, open-label, multicenter, study of WVT078 in subjects with relapsed and/or refractory multiple myeloma
bb2121 - A phase 3, multicenter, randomized, openlabel study to compare the efficacy and safety of BB2121 versus standard triplet regimens in subjects with relapsed and refractory multiple myeloma (RRMM) (KarMMa-3)
An open-label, multicenter, Phase I trial evaluating the safety and pharmacokinetics of escalating doses of RO7297089 in patients with relapsed or refractory multiple myeloma